← All trials
NCT03493698
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 7, 2018
- Primary completion
- Aug 27, 2018
- Completion date
- Aug 27, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 16
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Spring Bank Pharmaceuticals, Inc.Lead sponsor
- Pharmaceutical Research Associates, Inc. (PRA)Overall official - principal investigator
- Pharmaceutical Research Associates, Inc. (PRA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.